Article
Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer.
Oncology reports - 1 Jun 2012
Yang Guangdie, Yao Yinan, Zhou Jianya, Zhao Qiong
Abstract excerpt
Epidermal growth factor receptor (EGFR) is one of the most promising targets for non-small cell lung cancer (NSCLC). Our study demonstrated the antitumor effects of icotinib hydrochloride, a highly selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), in two EGFR-mutated lung cancer cell lines compared to A549, a cell line without EGFR mutations. We incubated PC-9 and HCC827 human lung...
Topics
- Antineoplastic Agents
- Apoptosis
- Carcinoma, Non-Small-Cell Lung
- Cell Line, Tumor
- Cell Movement
- Cell Proliferation
- Crown Ethers
- ErbB Receptors
- Gefitinib
- Humans
- Lung Neoplasms
- Mutation
- Quinazolines